Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 19/20 | 0.60 |
| ▸ | RPS6KA1 | Q15418 | 9/20 | 0.60 |
| ▸ | RPS6KB1 | P23443 | 8/20 | 0.60 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | GRK2 | P25098 | 7/20 | 0.43 |
| ▸ | GRK5 | P34947 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860928 | 0.94 | ROCK1 (0.68) | ROCK1RPS6KA1RPS6KB1GPBAR1CYP3A4 | |
| SCHEMBL3885355 | 0.88 | ROCK1 (0.68) | ROCK1RPS6KA1RPS6KB1ROCK2GRK2 | |
| SCHEMBL3887941 | 0.87 | ROCK1 (0.71) | ROCK1RPS6KA1RPS6KB1CYP3A4CYP2D6 | |
| SCHEMBL4322820 | 0.84 | ROCK1 (0.79) | ROCK1RPS6KA1RPS6KB1GPBAR1CYP3A4 | |
| SCHEMBL3885111 | 0.82 | ROCK1 (0.68) | ROCK1RPS6KA1RPS6KB1GPBAR1CYP3A4 | |
| SCHEMBL3895208 | 0.79 | ROCK1 (0.85) | ROCK1RPS6KA1RPS6KB1GPBAR1ROCK2 | |
| SCHEMBL3895928 | 0.78 | ROCK1 (0.76) | ROCK1RPS6KA1RPS6KB1CYP3A4CYP2D6 | |
| SCHEMBL3885403 | 0.78 | ROCK1 (0.79) | ROCK1RPS6KA1RPS6KB1CYP3A4CYP2D6 | |
| SCHEMBL3860866 | 0.77 | ROCK1 (0.50) | ROCK1RPS6KA1RPS6KB1GPBAR1CYP3A4 | |
| SCHEMBL3885671 | 0.77 | ROCK1 (0.50) | ROCK1RPS6KA1RPS6KB1GPBAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | claimed |
| EP-1718638-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | claimed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | claimed |
| EP-1718638-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005082890-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | claimed |
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1718638-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1718638-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082890-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058384-A1 | Novel Compounds | ARHGDIB, TNK2, ROCK2 | ROCK1 6/4885RPS6KA1 304/4885RPS6KB1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.